Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary

May 9, 2022

NASDAQ US Health Care Biotechnology earnings 49 min

Earnings Call Speaker Segments

David Szekeres

executive
#1

Thanks, Jason. Good afternoon, everybody, and I appreciate you all being with us. Joining me today from Heron are Barry Quart, our Chief Executive Officer and Chairman; John Poyhonen, President and Chief Commercial Officer; and Kimberly Manhard, Executive Vice President of Drug Development and a Board Director. If you're on the conference call, the slides are available through the webcast and you can also get to them by visiting the Investor Relations page on our website, and that will be after today's call wraps up. Before we get started, I want to remind everyone that forward-looking statements will be part of this call — things like Heron's future expectations, plans, prospects, corporate strategy and performance — and these count as forward-looking statements under the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from what those forward-looking statements indicate, due to a number of important factors, including the ones we discuss in our filings with the SEC. Also, any forward-looking statements reflect our views only as of today's webcast date and shouldn't be relied on as representing our views at any later date. We specifically disclaim any obligation to update such statements. Now I'll hand the call over to Barry.

Barry Quart

executive
#2

Thanks, David. Hello, everyone, and I appreciate you being here with us. The first quarter represented a pivotal moment in bringing ZYNRELEF to market, following the formal launch of broader indications secured in the middle of December. John will tell you that our ordering accounts have now achieved critical mass, with unit demand climbing 68% during the first quarter versus the fourth quarter. Because of this, we've been able to make considerable headway in bringing down surplus stockpiles at the distribution centers; as a result, in the upcoming quarter, dollar sales for 400-milligram vials ought to align with demand. As ordering accounts keep growing, formulary approvals continue, pass-through status remains in place, and several IDNs progress toward therapeutic interchange with ZYNRELEF, we expect comparable or even bigger sequential gains in the quarters ahead. Turning to our CINV franchise, consistent with what we mentioned last quarter, we saw modest growth and now feel confident enough in this market, following COVID-related disruptions, to issue guidance for the full year 2022. Throughout the first quarter, we kept advancing our NDA for HTX-019 for postoperative nausea — PONV — which could potentially be many times bigger than our CINV business. FDA has no pending information requests, and they've already given initial labeling comments. Finally, we've kept directing our efforts toward both lowering costs and securing partnerships outside U.S. territories for ZYNRELEF in order to lengthen our cash runway. We've achieved meaningful progress on both fronts, with the aim of finalizing at least one partnership during this quarter. All in all, the first quarter marked a significant turning point for Heron, and we were glad to walk you through our progress today. I'll now hand the call to John so he can go over our achievement of key commercial and corporate milestones. John?

John Poyhonen

executive
#3

Thanks, Barry. I'm glad to be able to walk you through the commercial results from our first quarter. With the ZYNRELEF launch, we keep achieving meaningful forward movement. In my remarks, I'll begin with several updates concerning the key performance metrics tied to that progress. After that, I'll close with news about the robust commercial performance in quarter one from our oncology care business. To begin, I'll recap the ZYNRELEF launch highlights so far by walking through our scorecard of leading indicators. Across the launch's first three quarters, we've maintained a solid pace of bringing on new unique ordering accounts, expanding by roughly 50 each month; we're likewise quite encouraged by gains in account reorder rates, which climbed from 50% during the launch's initial three months to 80% across the first nine months. We keep securing formulary approvals for ZYNRELEF at targeted hospitals, running at a pace of 32 approvals each month throughout our launch. Significantly, growth has been excellent when it comes to integrated delivery networks, or IDNs, adding ZYNRELEF to formulary. In our view, securing IDN support matters critically for possible therapeutic interchanges, as key accounts could in the future switch from Exparel to ZYNRELEF for procedures that are indicated. Lastly, since the previous earnings call, ZYNRELEF obtained pass-through status allowing separate reimbursement for it beyond the surgical bundle payment. That's a major competitive edge, because in the hospital outpatient care setting, ZYNRELEF stands alone as the local anesthetic that is separately reimbursed — a setting that accounts for an estimated 59% of our indicated procedures. Slide number 6 compares unique ordering accounts over the launch's first nine months, drawing on Symphony Health data. We keep adding accounts that order ZYNRELEF at a rapid clip, reaching 451 ordering accounts within the launch's first nine months. That's a 46% gain over the 309 figure seen at six months into launch; beyond that, 80% of accounts reordered ZYNRELEF during the first nine months, the highest reorder percentage among all four products examined in this benchmark. In our view, the rising reorder rate signals strongly that surgeons are having a great real world experience with their patients. Although these initial ZYNRELEF results are solid, expanding the number of ordering accounts aggressively remains a top priority for 2022. And on that goal, we kept making robust progress in April, as the next slide will show. During April, 61 new unique ordering accounts came on board, lifting the cumulative total to 512 across the launch's first 10 months. That account count means ZYNRELEF orders have come from 27% of the 1,900 accounts we target. ZYNRELEF unit demand rose 68% in quarter one compared with quarter four. Even so, it's crucial to note that the COVID Omicron surge held ZYNRELEF back from late December's second half through early February. Amid that surge, our customers encountered elective surgery delays stemming from policy decisions, positive patient pre-op COVID tests, and staff shortages. Even so, we managed to show growth on a monthly basis, reaching 42% in February and 25% in March. In Q1, demand units for the 200-milligram SKU rose more than 106%, driven by wider use of ZYNRELEF’s label indication, which applied that dosage strength for surgical procedures including bariatric foot and ankle. April marked the largest monthly demand total since launch, yet the month-over-month increase in April was slower than in the two preceding months of the first quarter. Our sales team reported a dip in elective procedures from late March through the first couple of weeks of April, which they attributed to spring break among patients and surgeons; to check that feedback, we examined the rolling five-week period ending April 15th against the preceding five-week period. As the demand slide indicates, ZYNRELEF rose 12% across that stretch, whereas Exparel fell 3% over the same stretch. Inventory levels for ZYNRELEF within the distribution channel remain something we watch closely. On our fourth quarter call, we noted excess initial stocking inventory sitting in the distribution channel. Since then, we have kept making meaningful headway in working through that inventory, thanks to higher ZYNRELEF demand unit volume sales. Net sales for the first quarter came to $1.1 million, after $300,000 in returns for short-dated product and ongoing progress drawing down the initial stocking inventory through demand orders from hospitals and ASCs; to gain a clearer picture of inventory level and the distribution channel, we report ex-factory reorder rates by demand unit volume for both SKUs. In the end, we aim for ex-factory orders to equal 100% of demand unit volume, which would mean the distribution channel replenishes inventory for each demand unit sold, whether hospital or ASC. As of March 31st, the reorder rate for the 400-milligram SKU stood at 92% of demand unit volume. Luckily, by March 3rd — sorry, May 3rd, the ex-factory order rate is now above 100% of the demand unit; put differently, the 400-milligram SKU has steadied, and going forward ZYNRELEF demand units ought to be reflected in ex-factory unit sales. Turning to the 200-milligram SKU, the reorder rate as of March 31st was 41%, which points to some excess 200-milligram inventory in the distribution channel at the close of the first quarter. That is not surprising given the 200-milligram SKU represented 26% of total ZYNRELEF demand unit volume. We have already seen substantial improvement in the 200-milligram ex-factory reorder through May 3rd, with a 67% ex-factory reorder rate, on the strength of accelerating growth for the 200-milligram SKU; we expect to work through the remaining excess 200-milligram inventory by the close of the second quarter, much as we did with the 400-milligram SKU during the first quarter. Now let’s dig into the specifics of our new business pipeline. This slide shows the continued rapid progress ZYNRELEF is making on formulary approvals. At the end of February, we reported 260 formulary approvals. Since the launch, that figure has kept climbing by roughly 30 fresh formulary approvals each month, reaching 319 in total. And among those accounts that are in fact making P&T decisions, more than 90% of hospital P&T committees are putting ZYNRELEF on formulary. Notably, an estimated 68% of the formulary approvals we have are for unrestricted use of ZYNRELEF. We're also seeing great momentum in broadening — securing expansion of that unrestricted formulary approval so it covers the wider label the FDA cleared in mid-December. Roughly 60 more P&T committees are set to review ZYNRELEF during the rest of the second quarter, before that quarter wraps up. On top of that, several hospitals and IDNs, which put in place a one year moratorium on adding any new products after FDA approval, will become open for P&T committee reviews during the third quarter. Fresh formulary approvals assist us in building a critical pipeline for new ZYNRELEF business and stay a key priority for our commercial team. Moving on, I'd like to call out a key top down strategy: targeting integrated delivery networks, or IDNs, to open up new system-wide opportunities for therapeutic interchange from Exparel to ZYNRELEF for indicated procedures. So far, 46 IDNs have placed ZYNRELEF on their formularies.

John Poyhonen

executive
#4

Within these IDN networks, you'll find more than 1,100 institutions, and 41% of the approvals for unrestricted ZYNRELEF use come from them. On top of that, roughly 676,000 procedures annually that are indicated for ZYNRELEF, plus 77 million in Exparel sales, are tied to those 46 IDNs. Because we've succeeded with IDNs, we're able to engage senior-level decision makers who are weighing a switch from Exparel to ZYNRELEF for indicated procedures; let's now take a closer look at the 13 IDNs showing interest in a possible therapeutic interchange. Given that ZYNRELEF's label indications have been expanded, it makes sense that IDNs want to save millions of dollars on a product that has actually shown superior clinical results compared with the standard of care, bupivacaine. We're excited to be working alongside both pharmacy and physicians to support their internal evaluations of ZYNRELEF. Out of the 13 IDNs we're interested in, 11 have already begun their internal trials with ZYNRELEF. Feedback so far on those trials has been extremely positive across a broad range of surgical procedures. Although advancing a large IDN does take time, we anticipate the first IDN therapeutic interchange decision will come by the end of this quarter. For us, CMS approving pass-through status so ZYNRELEF gets separate reimbursement for Medicare patients is a game-changer. Over the next three years, ZYNRELEF is the only local anesthetic that is separately reimbursed in the hospital outpatient setting of care. That's a major competitive edge, because we're now actually less expensive than using generic bupivacaine, and Exparel's pass-through status in the hospital outpatient setting of care lapsed years ago. This important approval adds to the reimbursement strengths we already have in place. During the fourth quarter, CMS gave ZYNRELEF a specific C-code, C9088, for separate reimbursement in the ASC setting of care, effective January 1, 2022, for permanent reimbursement, extending even past the typical three-year pass-through period. Our market access team has performed exceptionally well on reimbursement coverage from commercial and Medicaid payers. Outside the surgical bundle payment, we've already secured separate reimbursement for ZYNRELEF with more than 123 million covered lives and ASCs. And in certain cases, it's reimbursed in the hospital outpatient setting as well. One key part of our pricing strategy is that even absent separate reimbursement, our lower acquisition cost helps customers across settings of care where the drug may be paid for under the surgical bundle payment. On this next slide, we've shown many different versions previously. Today, I'll concentrate on the purchase price savings and the reimbursement benefits. Making the switch to ZYNRELEF delivers a cost savings of 25% to 32% based on the wholesale acquisition cost, or WAC, and a savings of 42% to 48% based on our 340B price offering compared Exparel. That's a massive financial incentive for customers to switch to ZYNRELEF. From a reimbursement standpoint, using ZYNRELEF is profitable with Medicare patients in the hospital outpatient and ASC settings of care. Given the tough economic climate we're facing, 340B facilities could see a financial gain exceeding $429 for each patient when they choose ZYNRELEF over Exparel. With these kinds of economic advantages, it makes sense that major IDNs have started therapeutic interchange reviews. That wraps up the ZYNRELEF portion, so let me share what our main goals are for 2022. Number one for us is capitalizing on the fresh label indications to accelerate growth. We'll get there by taking surgeons who already use the product and moving them into additional procedures. We're also seeing great momentum in facilities that already have ZYNRELEF on formulary, working to lift restrictions so it can be used across all our newly indicated surgical procedures. Goal number two involves driving more usage inside ordering accounts by getting more surgeons to use ZYNRELEF regularly. A lot of facilities first tried ZYNRELEF with just 2 or 3 surgeons from bigger practices. Because their patients have done so well, we've been actively drawing on those experiences to help build broader adoption of ZYNRELEF among their peers. Our third objective is securing formulary approvals at additional targeted IDNs and hospitals. Gaining more access in our pipeline for growth and therapeutic interchange possibilities sits at the heart of this aim. Last of all, we'll keep working to maximize our separate reimbursement for ZYNRELEF outside the surgical bundle payment. The April 1st pass-through status for ZYNRELEF in the hospital outpatient setting is already delivering a favorable effect. To sum up, we've already achieved solid progress on several leading indicators, and that gives us confidence 2022 will be a big growth year for ZYNRELEF. Now I want to change direction and go over the first quarter results from our oncology care franchise. In Q1, our oncology care team did a fantastic job, growing CINV portfolio net sales by 13% versus the previous quarter; that growth came from a 22% rise in CINVANTI demand units within the clinic setting of care, a market where generic competition dominates. For the second quarter of 2022, our CINV net sales guidance falls between $22 million and $23 million. That's because our gross to net revenue will be somewhat lower on the higher demand units sold in the quarter. We believe both CINVANTI and SUSTOL are positioned for growth in 2022, for 2 main reasons. First, we keep seeing better reimbursement tailwinds as generic fosaprepitant average sales price reimbursement has dropped to $26.35 in the second quarter of 2022; on top of that, as of January 1st, separate reimbursement in the hospital outpatient segment came to an end, making the CINVANTI value proposition far more appealing in 2022. IV Akynzeo's ASP reimbursement has fallen by more than $180 over the last year. That means there's less value they can deliver, which works in favor of both SUSTOL and CINVANTI. As Barry noted, we're now giving full-year 2022 CINV net sales guidance between $89 million and $93 million, which represents a 7% to 11% increase compared to the prior year. One possible positive factor comes from the shortage of IV bags that certain accounts are running into, and that works in favor of CINVANTI, since it is the sole NK-1 that does not need an IV infusion bag. On top of that, a buildup of oncology patients stemming from COVID exists, and our view is that this opens up chances for the two products, given that they are usable in HEC as well as for most MEC patients; as new patients come back into the system to get treatment, a major growth opportunity will emerge for the two products. That brings my prepared remarks to a close. At this point I will hand the call back to Barry. Barry?

Barry Quart

executive
#5

Thank you, John. During today's call, you've already heard the commercial figures from each of our product franchises. To close things out, though, looking at our financial slide, something of great interest to everybody as of March 31, 2022: our cash, cash equivalents and short-term investments came to $111.9 million, while accounts receivable stood at roughly $41 million. For the second quarter of 2022, we anticipate net cash used for operating activities somewhere between $37 million to $39 million. As the following slide notes, getting an ex-U.S. partnership done to strengthen the balance sheet ranks among our top priorities. Slide 20 lays out key catalysts for the Company. Chief among them: finishing an ex-U.S. partnership for ZYNRELEF, and completing the work required to submit sNDA2 for ZYNRELEF so its indications can be further expanded. On the CINV side, reaching 89 to $93 million in net product sales during 2022; and on the PONV side, securing FDA approval for HTX-019 by September. As mentioned, initial labeling comments for this NDA have already come in. Slides 21 and 22 provide important safety information regarding ZYNRELEF. Those slides can be found on our website. That said, we're ready to take your questions. Operator?

Brandon Folkes

analyst
#6

Could you perhaps explain the reason you're not securing formulary approval? What's driving those choices? Is it purely the label? Is it simply a matter of time, any detail at all? Then you brought up the priority of executing and an ex-U.S. partnership. Could you describe the landscape you're observing there, where you might secure a sizable upfront? Is this a landscape in which partners want to pay a sizable upfront? Thank you.

Barry Quart

executive
#7

Absolutely. I'll handle the second one and hand the formulary one to John. Regarding partnering, we have major partnering efforts in progress, which is why we had enough confidence to call it definitely a key catalyst on the horizon soon. And since we have multiple companies with conversations currently happening, late-stage conversations, I believe, we can confidently state that having major interest lets us seek major upfront payments from companies. So, I can't say a great deal beyond that. Yet certainly there's considerable interest in the product. Clearly, surgical procedures exist everywhere across the world. Being able to greatly lessen pain, get patients discharged from the hospital are all highly appealing endpoints. Not every place has an opioid crisis like the U.S. and Canada, yet pain remains a major problem worldwide; so, with that, John?

John Poyhonen

executive
#8

Absolutely. So to begin with, from the perspective of a P&T committee, I'd say our performance is extremely strong; more than 90% of the P&T committees that actually take a look at ZYNRELEF end up giving it the green light. On top of that, the count of approvals for unrestricted use keeps growing; so every one of those things is quite encouraging, Brandon. As for the accounts that aren't on board, I'd sort them into two main categories at this point. The first would be simply the ones — those operating under a moratorium tied to their own policy, where they won't approve any drug, and that means not only ZYNRELEF but any FDA-approved drug, until it has spent at least one year in the market, purely so they can build up experience with it. And luckily, that milestone is nearly here, and we'd anticipate reaching back out to quite a few of those accounts during the third quarter. The second group of customers declining to approve us consists mainly of accounts that right now rely on a generic combination — a sort of cocktail — that uses bupivacaine as the backdrop. And that's a situation we keep addressing, given that we hold superior clinical data from a head-to-head comparison against bupivacaine. We're attempting to make progress through the surgeons. Typically, pharmacy is the driver there, since they're focused on holding the line on budgets; but luckily, those represent fewer than 10% of the accounts out there, and we keep pushing on it by way of surgeon champions.

Brandon Folkes

analyst
#9

Thank you so much. Would it be okay if I pose just one additional question, since you brought up the topic of surgeon champions? Clearly, your account reorder rates appear quite strong. Can you share any observations regarding the actual surgeons working at those accounts? Are they using the product again or considering placing another order for it?

John Poyhonen

executive
#10

Sure. Excellent question. So, what we're observing is that we're achieving truly outstanding reorder rates, with 80% of accounts reordering ZYNRELEF within the initial nine months; so, that's really thrilling for us, though those are largely fueled by surgeons who began utilizing the account from sort of — or the product from the very first day; so, what we're learning from surgeons is that they're actually experiencing superior outcomes with ZYNRELEF compared to what was observed in our clinical trials, simply because of certain restrictions we faced regarding the capacity to employ multimodal analgesics. So, the response from them has been incredible. I recently had a conversation with a surgeon last week, who had in fact been a former Exparel user and had just completed, over the past several months, 400 patients with ZYNRELEF and simply remarked, this is an absolute game-changer for his practice and his patients.

Josh Schimmer

analyst
#11

Josh, thanks for that.

Barry Quart

executive
#12

I'll take the second question first. As I mentioned, our main objective at this moment is to finalize at least one partnering deal—possibly more—since we think those will be extremely important for meeting our financing requirements. We'd like to have those wrapped up before considering any alternative financing options. Is it possible we could fulfill our financing needs through those partnering events? We've definitely come a long way. That's why we haven't pursued anything else. Partnering processes, as you're aware, tend to take somewhat more time than anticipated, but we expect to close one or several of them in the near future. Now, regarding how ZYNRELEF is doing, I believe we gave quite clear guidance last quarter: due to the excess inventory, the first-quarter objective was really to drive demand units and use. However, that likely wouldn't show up in dollar sales, since we had to reduce that excess inventory. As John mentioned, we've made considerable headway in fully clearing the excess inventory for the 400 at this point, and we're making considerable headway on the 200. And we will certainly attempt to offer as much detail as possible regarding anticipated sales moving forward. Clearly, this is a highly dynamic time right now, and I think I'll let John share his perspective too. But one factor that definitely slowed the launch was the initial label. We've taken care of that now. Then the second issue we encountered, which was somewhat unforeseen, is that virtually all of our major customers want to conduct their own evaluation of the product before proceeding aggressively. Those evaluations require time, as John mentioned, for the IDN interchange process. They're all proceeding with their own internal evaluations. The feedback we've received has been quite positive. So we aren't worried that they want to conduct their own evaluations. It simply requires a great deal of time. And so, we're hopefully nearing the end of that first process for an IDN switch, and hopefully the others will come along relatively soon afterward. John, would you like to add anything else?

John Poyhonen

executive
#13

Absolutely. Let me give you a little more detail on that, Barry. Thanks. From where I sit, Josh, when you examine several different metrics, the access and formulary approvals have performed very strongly. The count of ordering accounts has also been performing very strongly, and the reimbursement we've secured — not just through obtaining pass-through status, but also with commercial and Medicaid payers — is excellent. On top of that, the reorder rate is excellent. The place where we're falling short of our objective at this point, I'd say, is that we'd prefer to be driving more volume per account than we currently are. I believe there are a few explanations for that. First, as Barry mentioned, we launched with three indicated procedures, and although market research suggested surgeons would use it widely off label, that isn't what occurred in practice. We're now beginning to observe that shift. Second, there's the internal assessment piece. Quite a few accounts got misled by a prior competitor that entered the market promising them 72 hours of coverage when it actually delivers only 24. As a result, they needed to witness with their own eyes what ZYNRELEF was capable of. Thankfully, ZYNRELEF has been delivering excellent outcomes for their patients. So generating the volume levels on a per-account basis has taken longer than we'd like; however, the remaining metrics we're monitoring, I believe, are progressing quite well.

Serge Belanger

analyst
#14

I have four things to ask about ZYNRELEF. To start, could you describe the places where you've observed updates on the product up to now, with regard to procedures and the setting of care? Next, a follow-up regarding something you said earlier. You mentioned that moving from formulary acceptance to ordering and then usage takes more time than anticipated. Could you perhaps walk through that process, and is there any method by which it might be accelerated? Thank you.

Barry Quart

executive
#15

John, would you like to handle those?

John Poyhonen

executive
#16

Alright, my apologies. Would you mind going over that initial question again? I was busy jotting down the one you asked after it, Serge.

Barry Quart

executive
#17

When it comes to arranging care, what procedures are we observing, and in what locations?

John Poyhonen

executive
#18

Absolutely, Barry — thanks. When you take a step back and look at the whole picture, out of those 512 ordering accounts we have, roughly 58% are hospitals, while 42% are ASCs. That 58% hospital group is where 76% of our business comes from. So clearly, the remaining 24% is what the ASCs bring in. As for which procedures are being performed, I'd say we got a huge advantage early on from the first three indications — total knee replacement, hernia, and bunionectomy — so it makes sense those are the big volume drivers. With the label expansion, what we observed in Q1 is a genuine uptick in total hip replacements, and the outcomes there have been outstanding; we're also seeing quite a bit of bariatric surgery plus foot and ankle procedures. Those would be the main volume drivers when you look at it from a procedure perspective. Now, on the process side, getting a formulary approval is really just step one. After that comes a medical executive approval, which typically runs around 30 days. Then you need to be entered into the computerized order entry system. The pharmacy has to place the order, and it has to reach the patient. But what I believe we're witnessing at this moment is that a lot of these accounts will greenlight the product, ZYNRELEF, and then run an internal trial evaluation; that could involve just one surgical procedure, or it could span several, with them doing somewhere between 5 and 10 and 20 procedures to gauge how well it performs and whether it truly lives up to that 72-hour promise we make. Luckily, those are going quite well, though they typically begin with just two or three surgeons. So it takes time to work through that whole process and complete their initial evaluation, and after that they want follow-up visits with those patients. So it moves slower than we'd prefer, but what we're observing is that thanks to the fantastic results they're achieving with patients, we can leverage that experience with their peers to bring new surgeons on board. And I think one of the genuine upsides we'll see for the rest of 2022 is that as these trials keep going and the results stay positive, an increasing number of surgeons will adopt it. That will have a major effect on driving volume at each individual account, along with growing the number of procedures for which a surgeon chooses ZYNRELEF.

Serge Belanger

analyst
#19

Here's another one for Barry. When we look at partnerships outside the U.S., could you remind everyone which markets have cleared the product, and in which ones a filing has been made? Also, would you anticipate that this partnership meaningfully lengthens your cash runway, or are there additional options being considered as well? Thanks.

Barry Quart

executive
#20

Yes, sure. The product has clearance in Canada, in the European Union, and in a number of other nations that recognize the European Union's approval, Iceland among them. Regarding the data package we hold, it is ready for submission in plenty of additional nations. We simply haven't gone ahead and filed the product in those other nations yet, though we are talking with companies about pursuing that. So the absence of approval for the product in a given region hasn't stood in the way of locating companies eager to pursue progress there. And as I mentioned, the aim is, via one or more partnerships, to achieve meaningful improvement in the Company's financial situation. We keep examining options for lowering burn. That's the further avenue. Then, clearly, after both of those efforts are finished, we'll examine whether a remaining gap exists that must be addressed by some other means. And we will of course assess every possible path and make certain we pursue — take the optimal path for shareholders, and at the present share price, turning to equity certainly ranks quite low among the things we would choose to do.

Boris Peaker

analyst
#21

To start, I'd like to get a clearer picture. From what I gather, there's a monetary upside to choosing ZYNRELEF within the hospital environment versus certain other medications on the market. Could you verify whether that's the case? Also, is there any indication that this is influencing revenue? What's holding it back from pushing more hospital uptake than what we've observed up to now?

Barry Quart

executive
#22

John, would you like to handle that one?

John Poyhonen

executive
#23

Absolutely. So there are truly a few different lenses through which to view this, Boris. You've got that right. When ZYNRELEF is used in the hospital outpatient setting, a financial incentive does exist; the first piece is Medicare reimbursement, since payment is in fact made for ZYNRELEF in that context. Among local anesthetics, ZYNRELEF stands alone as the one Medicare patients can get reimbursed for in the hospital outpatient care setting. And when you examine it, at a hospital that isn't 340B, each time a 400-milligram vial of ZYNRELEF is used, you earn roughly $12.50; at a 340B hospital, you earn close to $75 on each vial. So the benefit there is quite substantial. Compare that against something like Exparel, where, absent any reimbursement beyond the surgical bundle, using their WAC price means a cost of $354. So that's a major advantage. And if you consider the hospital setting where reimbursement comes packaged within the surgical bundle, since we offer a meaningful edge both on the WAC side and on the 340B side, with the 400-milligram you can save roughly $87 per unit relative to choosing Exparel, and under 340B that figure reaches $149, or 42%. So from both the cost-savings angle and the reimbursement angle, we deliver something that genuinely works in the hospital's favor. On the question of why adoption hasn't moved faster: if you look at it, pass-through status was only granted to us on April 1st of this year. So benefits are already beginning to show up, with accounts seeking to move more quickly. So my expectation is that you'll begin to see growth in the hospital setting of care accelerate as we move ahead.

Boris Peaker

analyst
#24

Understood. My follow-up concerns the financial approach. Might you be looking at merely divesting royalty streams, or potentially offloading the entire — I'm unsure whether these count as non-core holdings or essentially the chemotherapy plus nausea management business — or has that option been ruled out for now?

Barry Quart

executive
#25

Sure. Boris, I'd say it's fair to describe our position as reviewing every possible path, with partnership capital that avoids dilution serving as our main objective. We have strong confidence in our ability to land meaningful agreements in that area. After that, to repeat what I mentioned earlier, when our expense reduction efforts are finished, the cash burn is lowered, and sizable upfront payments from partnerships come in, we'll assess the remaining shortfall and draw on one of multiple options to close whatever portion of it is left.

Kelly Shi

analyst
#26

Regarding ZYNRELEF, when you separate reorders into the 400-milligram and 200-milligram strengths, the rates right now are 92% and 41%, and that looks steady compared with Q4. What I'd like to know is how the reorder figure for the 200-milligram version might move as we go through 2022. Tied to that, I have a question about whether the financial motivation attached to 200 versus 400 is comparable when measured in dollars, both for hospitals and in the 340B context.

David Szekeres

executive
#27

John, would you like to address that?

John Poyhonen

executive
#28

Absolutely, Kelly. To begin with, I'd point out that the cost for each milligram is essentially the same whether you're talking about the 400 or the 200. That means a hospital gains nothing financially by choosing one over the other. What I believe you're observing regarding utilization — with 26% of our business having come from the 200-milligram since it launched — truly just reflects the fact that only a single FDA-indicated procedure, bunionectomy, relied on the 200-milligram. Once we broadened the label in mid-December, we began to witness quite substantial expansion in the 200-milligram. In fact, it rose by more than 106% across the first quarter; so its expansion is speeding up. Much of that involves small to medium abdominal surgeries, plus foot and ankle surgeries, which can now be done but were not initially, given the FDA's indication constraints. Therefore, what we anticipate is that we've already witnessed quite substantial expansion, finishing the first quarter with a 41% reorder rate on the 200-milligram. As of May 3rd alone, we've reached 67%. And once this quarter closes, our expectation is that we ought to have cleared out the 200-milligram inventory. So we're achieving excellent momentum on that front. Should you have any additional questions, just tell me.

Kelly Shi

analyst
#29

Thanks. Additionally, might you provide some insight into how the volume breaks down as well as the dollar amount when it comes to relative usage in the hospital versus the hospital and ambulance center environments?

John Poyhonen

executive
#30

Sure. As things stand, from a demand perspective, the division is 76% for the hospital outpatient environment — or the hospital as a whole in the case of the 400-milligram — while 24% of the volume sits in the ASC. They're quite comparable. There doesn't appear to be any meaningful gap between the ASC and the hospital; it's likely somewhat greater, I'm certain, when you consider that ZYNRELEF's total rate since launch is 26% inside the ASC market. Perhaps somewhere in the range of 30% to 32% would in fact fall within the ASC for the 200, and the reason is that bunionectomy would generally be performed in more of an ASC environment rather than a hospital outpatient one.

Barry Quart

executive
#31

Thanks. And I appreciate all of you for being with us on today's call. We're quite happy with how things went during this quarter, and we look forward to bringing you further updates.

Operator

operator
#32

That brings this conference to a close. We appreciate your participation in today's presentation. You are welcome to stay on the line.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.